Opendata, web and dolomites

FAIR-PARK-II SIGNED

Conservative iron chelation as a disease-modifying strategy in Parkinson’s disease: a multicentric, parallel-group, placebo-controlled, randomized clinical trial of deferiprone

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 FAIR-PARK-II project word cloud

Explore the words cloud of the FAIR-PARK-II project. It provides you a very rough idea of what is the project "FAIR-PARK-II" about.

neurons    score    symptomatic    innovation    brain    handicap    levels    cell    biological    prototypic    disorders    progression    radiological    therapy    frequent    criterion    models    probing    exposed    excess    novo    effect    pd    period    primary    parallel    prompt    multicentre    translational    powerful    movement    mg    inhibition    dfp    transferase    compacta    conservative    neurodegenerative    economics    tetrahydropyridine    catechol    deferiprone    unified    demonstrated    pilot    clinical    disease    primarily    diseases    efficacy    chelation    trial    rating    industrial    patients    society    secondary    siderosis    neuroprotection    dopaminergic    mitochondrial    dose    placebo    dopamine    biomarkers    detected    methyl    national    baseline    drug    impacts    pars    motor    societal    moderate    health    slows    model    wash    weeks    stress    mouse    parkinson    communicable    total    surrogate    regional    2nd    reduces    disorder    linked    scores    randomized    induces    worldwide    preclinical    academic    international    modifying    nigra    oxidative    antioxidant    de    17    kg    substantia    chronic    iron    group    treatment    day    followed    phenyl    systemic    metabolism   

Project "FAIR-PARK-II" data sheet

The following table provides information about the project.

Coordinator
CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE LILLE 

Organization address
address: AVENUE OSCAR LAMBRET 2
city: LILLE
postcode: 59037
website: http://www.chru-lille.fr/

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website http://www.fairpark2.eu/
 Total cost 8˙263˙202 €
 EC max contribution 5˙998˙994 € (73%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-PHC-2014-two-stage
 Funding Scheme RIA
 Starting year 2015
 Duration (year-month-day) from 2015-05-01   to  2021-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE LILLE FR (LILLE) coordinator 2˙662˙169.00
2    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) participant 642˙888.00
3    INSERM - TRANSFERT SA FR (PARIS) participant 389˙491.00
4    CHRISTIAN-ALBRECHTS-UNIVERSITAET ZU KIEL DE (KIEL) participant 351˙882.00
5    ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK FR (PARIS) participant 331˙848.00
6    UNIVERSITY OF NEWCASTLE UPON TYNE UK (NEWCASTLE UPON TYNE) participant 313˙370.00
7    STICHTING KATHOLIEKE UNIVERSITEIT NL (NIJMEGEN) participant 256˙250.00
8    MEDIZINISCHE UNIVERSITAT INNSBRUCK AT (INNSBRUCK) participant 226˙735.00
9    FUNDACIO CLINIC PER A LA RECERCA BIOMEDICA ES (BARCELONA) participant 196˙773.00
10    INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES PT (LISBOA) participant 187˙083.00
11    UNIVERZITA KARLOVA CZ (PRAHA 1) participant 145˙000.00
12    UNIVERSITAET ULM DE (ULM) participant 90˙000.00
13    SORBONNE UNIVERSITE FR (PARIS) participant 82˙550.00
14    PHILIPPS UNIVERSITAET MARBURG DE (MARBURG) participant 74˙875.00
15    EBERHARD KARLS UNIVERSITAET TUEBINGEN DE (TUEBINGEN) participant 48˙078.00
16    APO-PHARMA INC CORP CA (Toronto) participant 0.00
17    UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6 FR (PARIS) participant 0.00

Map

 Project objective

Parkinson’s disease (PD) is a major, chronic, non-communicable disease and the 2nd most frequent neurodegenerative disorder worldwide. Excess iron is primarily detected in the substantia nigra pars compacta, where dopaminergic neurons are exposed to high levels of oxidative stress produced by mitochondrial disorders and dopamine metabolism. Our previous preclinical, translational and pilot clinical studies demonstrated that novel iron chelation therapy with the prototypic drug deferiprone (DFP) (i) induces neuroprotection in cell models of PD via a powerful antioxidant effect, (ii) reduces regional siderosis of the brain, (iii) reduces motor handicap via inhibition of catechol-o-methyl transferase, and (iv) slows the progression of motor handicap in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model and in early PD patients. This project now seeks to demonstrate that conservative iron chelation therapy with moderate-dose DFP (30 mg/kg/day) slows the progression of handicap in de novo PD patients while not affecting systemic parameters. The 9-month, parallel-group, randomized, placebo-controlled, multicentre trial will be followed by a 1-month wash-out period. The primary efficacy criterion will be the change in motor and non-motor handicap scores on the Total Movement Disorders Society Unified Parkinson’s Disease Rating Scale to identify disease-modifying and symptomatic effects. The secondary efficacy criterion will be the change in score between baseline and 40 weeks (i.e. probing the disease-modifying effect only). Potential surrogate radiological and biological biomarkers, health economics and societal impacts will be assessed. 17 national, European and international research and innovation activities will be linked with the project. The study results should prompt academic and industrial research on iron chelation as a disease-modifying treatment in neurodegenerative diseases.

 Deliverables

List of deliverables.
Communication and Dissemination tools including website Websites, patent fillings, videos etc. 2020-02-17 17:47:27

Take a look to the deliverables list in detail:  detailed list of FAIR-PARK-II deliverables.

 Publications

year authors and title journal last update
List of publications.
2019 MHD Rami Al Shweiki, Petra Steinacker, Patrick Oeckl, Bastian Hengerer, Adrian Danek, Klaus Fassbender, Janine Diehl-Schmid, Holger Jahn, Sarah Anderl-Straub, Albert C. Ludolph, Carlos Schönfeldt-Lecuona, Markus Otto
Neurofilament light chain as a blood biomarker to differentiate psychiatric disorders from behavioural variant frontotemporal dementia
published pages: 137-140, ISSN: 0022-3956, DOI: 10.1016/j.jpsychires.2019.03.019
Journal of Psychiatric Research 113 2020-02-17
2017 Patrick Oeckl, Petra Steinacker, Markus Otto
Comparison of Internal Standard Approaches for SRM Analysis of Alpha-Synuclein in Cerebrospinal Fluid
published pages: 516-523, ISSN: 1535-3893, DOI: 10.1021/acs.jproteome.7b00660
Journal of Proteome Research 17/1 2020-02-17
2018 Johannes Denk, Felix Oberhauser, Johannes Kornhuber, Jens Wiltfang, Klaus Fassbender, Matthias L. Schroeter, Alexander E. Volk, Janine Diehl-Schmid, Johannes Prudlo, Adrian Danek, Bernhard Landwehrmeyer, Martin Lauer, Markus Otto, Holger Jahn
Specific serum and CSF microRNA profiles distinguish sporadic behavioural variant of frontotemporal dementia compared with Alzheimer patients and cognitively healthy controls
published pages: e0197329, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0197329
PLOS ONE 13/5 2020-02-17
2017 Carina Lehmer, Patrick Oeckl, Jochen H Weishaupt, Alexander E Volk, Janine Diehl‐Schmid, Matthias L Schroeter, Martin Lauer, Johannes Kornhuber, Johannes Levin, Klaus Fassbender, Bernhard Landwehrmeyer, Martin H Schludi, Thomas Arzberger, Elisabeth Kremmer, Andrew Flatley, Regina Feederle, Petra Steinacker, Patrick Weydt, Albert C Ludolph, Dieter Edbauer, Markus Otto, Adrian Danek, Emily Feneber
Poly‐ GP in cerebrospinal fluid links C9orf72 ‐associated dipeptide repeat expression to the asymptomatic phase of ALS / FTD
published pages: 859-868, ISSN: 1757-4676, DOI: 10.15252/emmm.201607486
EMBO Molecular Medicine 9/7 2020-02-17
2017 Viviana Carcamo Yañez, Jens Göpfert, Markus Otto, Hayrettin Tumani, Andreas Peter, Thomas Joos
Development and Validation of an Ultrasensitive Procalcitonin Sandwich Immunoassay
published pages: 18, ISSN: 2571-5135, DOI: 10.3390/ht6040018
High-Throughput 6/4 2020-02-17
2018 Francisco Oliveira, Antoine Leuzy, João Castelhano, Konstantinos Chiotis, Steen Gregers Hasselbalch, Juha Rinne, Alexandre Mendonça, Markus Otto, Alberto Lleó, Isabel Santana, Jarkko Johansson, Sarah Anderl-Straub, Christine Arnim, Ambros Beer, Rafael Blesa, Juan Fortea, Herukka Sanna-Kaisa, Erik Portelius, Josef Pannee, Henrik Zetterberg, Kaj Blennow, Ana P. Moreira, Antero Abrunhosa, Agneta N
Data driven diagnostic classification in Alzheimer\'s disease based on different reference regions for normalization of PiB-PET images and correlation with CSF concentrations of Aβ species
published pages: 603-610, ISSN: 2213-1582, DOI: 10.1016/j.nicl.2018.08.023
NeuroImage: Clinical 20 2020-02-17
2019 Shashank Masaldan, Ashley I. Bush, David Devos, Anne Sophie Rolland, Caroline Moreau
Striking while the iron is hot: Iron metabolism and ferroptosis in neurodegeneration
published pages: 221-233, ISSN: 0891-5849, DOI: 10.1016/j.freeradbiomed.2018.09.033
Free Radical Biology and Medicine 133 2020-02-17
2016 Patrick Oeckl, Fabian Metzger, Magdalena Nagl, Christine A.F. von Arnim, Steffen Halbgebauer, Petra Steinacker, Albert C. Ludolph, Markus Otto
Alpha-, Beta-, and Gamma-synuclein Quantification in Cerebrospinal Fluid by Multiple Reaction Monitoring Reveals Increased Concentrations in Alzheimer′s and Creutzfeldt-Jakob Disease but No Alteration in Synucleinopathies
published pages: 3126-3138, ISSN: 1535-9476, DOI: 10.1074/mcp.m116.059915
Molecular & Cellular Proteomics 15/10 2020-02-17
2018 Minh H. Pham, Elke Warmerdam, Morad Elshehabi, Christian Schlenstedt, Lu-Marie Bergeest, Maren Heller, Linda Haertner, Joaquim J. Ferreira, Daniela Berg, Gerhard Schmidt, Clint Hansen, Walter Maetzler
Validation of a Lower Back “Wearable”-Based Sit-to-Stand and Stand-to-Sit Algorithm for Patients With Parkinson\'s Disease and Older Adults in a Home-Like Environment
published pages: , ISSN: 1664-2295, DOI: 10.3389/fneur.2018.00652
Frontiers in Neurology 9 2020-02-17
2017 Laetitia Thibault, Olivier Rascol, Jean-Christophe Corvol, Joaquim Ferreira, Luc Defebvre, Dominique Deplanque, Régis Bordet, Caroline Moreau, David Devos
New perspectives on study designs for evaluating neuroprotection in Parkinson\'s disease
published pages: 1365-1370, ISSN: 0885-3185, DOI: 10.1002/mds.27055
Movement Disorders 32/10 2020-02-17
2018 Caroline Moreau, James A. Duce, Olivier Rascol, Jean-Christophe Devedjian, Daniela Berg, David Dexter, Z. Ioav Cabantchik, Ashley I. Bush, David Devos
Iron as a therapeutic target for Parkinson\'s disease
published pages: 568-574, ISSN: 0885-3185, DOI: 10.1002/mds.27275
Movement Disorders 33/4 2020-02-17
2017 Anahita Fathi Kazerooni, Mahnaz Nabil, Mehdi Zeinali Zadeh, Kavous Firouznia, Farid Azmoudeh-Ardalan, Alejandro F. Frangi, Christos Davatzikos, Hamidreza Saligheh Rad
Characterization of active and infiltrative tumorous subregions from normal tissue in brain gliomas using multiparametric MRI
published pages: , ISSN: 1053-1807, DOI: 10.1002/jmri.25963
Journal of Magnetic Resonance Imaging 2020-02-17
2018 João C.P. Santiago, Markus Otto, Werner Kern, Paul Christian Baier, Manfred Hallschmid
Relationship between cerebrospinal fluid concentrations of orexin A/hypocretin-1 and body composition in humans
published pages: 26-30, ISSN: 0196-9781, DOI: 10.1016/j.peptides.2018.02.005
Peptides 102 2020-02-17
2017 Anja Hviid Simonsen, Sanna-Kaisa Herukka, Niels Andreasen, Ines Baldeiras, Maria Bjerke, Kaj Blennow, Sebastiaan Engelborghs, Giovanni B. Frisoni, Tomasz Gabryelewicz, Samantha Galluzzi, Ron Handels, Milica G. Kramberger, Agnieszka Kulczyńska, Jose Luis Molinuevo, Barbara Mroczko, Agneta Nordberg, Catarina Resende Oliveira, Markus Otto, Juha O. Rinne, Uroš Rot, Esen Saka, Hilkka Soininen, Hanne
Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia
published pages: 274-284, ISSN: 1552-5260, DOI: 10.1016/j.jalz.2016.09.008
Alzheimer\'s & Dementia 13/3 2020-02-17

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FAIR-PARK-II" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "FAIR-PARK-II" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

ENDOSCAPE (2019)

ENDOSCAPE, a clinically applicable non-viral gene delivery technology

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More